| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0360-3016(01)01477-8 |
| P698 | PubMed publication ID | 11380213 |
| P50 | author | Rodney J. Hicks | Q43224607 |
| P2093 | author name string | J P Matthews | |
| A F McKenzie | |||
| A Hogg | |||
| D L Ball | |||
| M P MacManus | |||
| R E Ware | |||
| A Wirth | |||
| P2860 | cites work | Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose. The Members of the PET-Lung Tumor Study Group | Q72765709 |
| Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer | Q72824402 | ||
| A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial | Q73218411 | ||
| Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography | Q73293360 | ||
| Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer | Q77181931 | ||
| Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer | Q77361527 | ||
| Detection of extrathoracic metastases by positron emission tomography in lung cancer | Q77399187 | ||
| Revisions in the International System for Staging Lung Cancer | Q28241070 | ||
| Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer | Q33534399 | ||
| Metastases from non-small cell lung cancer: mediastinal staging in the 1990s--meta-analytic comparison of PET and CT. | Q33879258 | ||
| The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer | Q34051322 | ||
| Long-term survival following surgical treatment of solitary brain metastasis in non-small cell lung cancer | Q40939684 | ||
| Does resection of adrenal metastases from non-small cell lung cancer improve survival? | Q43583972 | ||
| Characteristics of 49 patients who survived for 5 years following radical radiation therapy for non-small cell lung cancer: the potential for cure | Q44270777 | ||
| Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. | Q53814690 | ||
| Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography | Q71002390 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | lung cancer | Q47912 |
| adaptive radiation therapy | Q180507 | ||
| P304 | page(s) | 287-293 | |
| P577 | publication date | 2001-06-01 | |
| P1433 | published in | International Journal of Radiation Oncology Biology Physics | Q2296252 |
| P1476 | title | High rate of detection of unsuspected distant metastases by pet in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy | |
| P478 | volume | 50 |
| Q42786728 | 18-Fluorodeoxyglucose positron emission tomography as a tool for response prediction in solid tumours |
| Q37016566 | 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: a systematic review |
| Q35050792 | A Phase II Comparative Study of Gross Tumor Volume Definition With or Without PET/CT Fusion in Dosimetric Planning for Non–Small-Cell Lung Cancer (NSCLC): Primary Analysis of Radiation Therapy Oncology Group (RTOG) 0515 |
| Q41053874 | A Prospective Study Comparing Functional Imaging (18F-FDG PET) Versus Anatomical Imaging (Contrast Enhanced CT) in Dosimetric Planning for Non-small Cell Lung Cancer |
| Q48141815 | Additional Value of Whole-Body Fluorodeoxyglucose Positron Emission Tomography in the Detection of Distant Metastases of Non–Small-Cell Lung Cancer |
| Q47138202 | Anatomic, functional and molecular imaging in lung cancer precision radiation therapy: treatment response assessment and radiation therapy personalization |
| Q38369700 | Asymptomatic skeletal muscle metastases from non-small cell lung cancer |
| Q36182345 | Bone matters in lung cancer |
| Q40594149 | Clinical evaluation of proton radiotherapy for non-small-cell lung cancer |
| Q30250349 | Clinical utility of F-18 FDG PET-CT in the initial evaluation of lung cancer |
| Q38550641 | Colonic metastasis from primary carcinoma of the lung: report of a case and review of Japanese literature |
| Q50149774 | Comparison of CT and positron emission tomography/CT coregistered images in planning radical radiotherapy in patients with non-small-cell lung cancer |
| Q34892288 | Correlation of the apparent diffusion coefficient (ADC) with the standardized uptake value (SUV) in lymph node metastases of non-small cell lung cancer (NSCLC) patients using hybrid 18F-FDG PET/MRI |
| Q42232269 | Current concepts in F18 FDG PET/CT-based radiation therapy planning for lung cancer |
| Q91780726 | Cutaneous Metastasis from Visceral Organs: 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Scan Aiding in Localizing Primary Site |
| Q56994721 | Delivering affordable cancer care in high-income countries |
| Q38396160 | Diagnostic evaluation for interventional bronchoscopists and radiologists in lung cancer practice. |
| Q44207255 | Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer |
| Q57758990 | Early mortality after radical radiotherapy for non-small-cell lung cancer: comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center |
| Q53376866 | Endoscopic ultrasound-guided fine-needle aspiration when combined with positron emission tomography improves specificity and overall diagnostic accuracy in unexplained mediastinal lymphadenopathy and staging of non-small-cell lung cancer. |
| Q42764860 | Evolution and science, progress and change |
| Q43732874 | F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment |
| Q36111424 | FDG-PET/CT Limited to the Thorax and Upper Abdomen for Staging and Management of Lung Cancer. |
| Q37652687 | FDG-PET/CT imaging for tumor staging and definition of tumor volumes in radiation treatment planning in non-small cell lung cancer |
| Q37231172 | Fluorodeoxyglucose positron-emission tomography ratio in non-small cell lung cancer patients treated with definitive radiotherapy |
| Q58594704 | Greater reduction in mid-treatment FDG-PET volume may be associated with worse survival in non-small cell lung cancer |
| Q36243952 | Haematogenous muscular metastasis of non-small cell lung cancer in F-18 fluorodeoxyglucose positron emission tomography/computed tomography |
| Q35198440 | Image-guided conformal radiation therapy planning and delivery for non-small-cell lung cancer |
| Q36735010 | Imaging in the diagnosis and treatment of non-small cell lung cancer |
| Q34390410 | Impact of FDG-labelled positron emission tomography imaging on the management of non-small-cell lung cancer |
| Q81430746 | Importance of local control in an era of systemic therapy |
| Q57780606 | Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer |
| Q36990569 | Isolated asymptomatic skeletal muscle metastasis in a potentially resectable non-small cell lung cancer: detection with FDG PET-CT scanning |
| Q35186819 | Lung cancer 7: management of lung cancer in elderly patients |
| Q38007233 | Mediastinal staging of lung cancer: novel concepts |
| Q38172913 | Minimally invasive mediastinal staging of non-small-cell lung cancer: emphasis on ultrasonography-guided fine-needle aspiration |
| Q38155852 | Modern diagnostic and therapeutic interventional radiology in lung cancer |
| Q35737357 | Modern hepatic imaging |
| Q55182174 | Molecular Imaging in Oncology Using Positron Emission Tomography. |
| Q47654225 | Monte Carlo-based lung cancer treatment planning incorporating PET-defined target volumes |
| Q36586494 | Multimodality therapy for Pancoast tumor |
| Q37927164 | Novel molecular imaging in lung and pleural diseases |
| Q33945401 | Oncologic positron emission tomography: a surgical perspective. |
| Q37732292 | PET and PET-CT in radiation treatment planning for lung cancer |
| Q35581362 | PET scan in the staging of non-small cell lung cancer |
| Q84379472 | PET-CT in the staging and treatment of non-small-cell lung cancer |
| Q42945884 | PET/CT: will it change the way that we use CT in cancer imaging? |
| Q34660746 | Pancoast tumors: characteristics and preoperative assessment |
| Q34447453 | Positron emission tomography (PET) of non-small cell lung cancer |
| Q46981176 | Positron emission tomography imaging in nonsmall-cell lung cancer |
| Q42056666 | Positron emission tomography in the management of lung cancer |
| Q35684131 | Positron emission tomography in the management of non-small cell lung cancer |
| Q33657999 | Positron emission tomography/computerized tomography in lung cancer |
| Q37227687 | Prediction of survival by [18F]fluorodeoxyglucose positron emission tomography in patients with locally advanced non-small-cell lung cancer undergoing definitive chemoradiation therapy: results of the ACRIN 6668/RTOG 0235 trial |
| Q53090112 | Pretreatment maximum standardized uptake value on 18F-fluorodeoxyglucose positron emission tomography is a predictor of outcome for stage I non-small cell lung cancer after stereotactic body radiotherapy. |
| Q79745325 | Radiation therapy |
| Q35543221 | Radiation therapy alone in early stage non‐small cell lung cancer |
| Q74619608 | Radiotherapy alone in technically operable, medically inoperable, early-stage (I/II) non-small-cell lung cancer |
| Q36516767 | Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer |
| Q36780556 | Role of PET-CT in the optimization of thoracic radiotherapy. |
| Q46186435 | Role of positron emission tomography in lung cancer. |
| Q47284858 | SEOM-SERAM-SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer. |
| Q36129173 | Staging non-small cell lung cancer |
| Q51930484 | Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer. |
| Q27001239 | The Utility of Metabolic Imaging by 18F-FDG PET/CT in Lung Cancer: Impact on Diagnosis and Staging |
| Q57172944 | The developing role of FDG PET imaging for prognostication and radiotherapy target volume delineation in non-small cell lung cancer |
| Q90175125 | The evolving role of radiotherapy in non-small cell lung cancer |
| Q37131297 | The mediastinal staging accuracy of 18F-Fluorodeoxyglycose positron emission tomography/computed tomography in non-small cell lung cancer with variable time intervals to surgery |
| Q84582192 | The multidisciplinarity of stage III non-small cell lung cancer |
| Q37210598 | The role of positron emission tomography in the management of non-small cell lung cancer. |
| Q37785001 | The use of FDG-PET to target tumors by radiotherapy |
| Q53553878 | Thoracic staging of non-small-cell lung cancer using integrated (18)F-FDG PET/MR imaging: diagnostic value of different MR sequences. |
| Q37423919 | Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cance |
| Q36245361 | Utility of FMISO PET in advanced head and neck cancer treated with chemoradiation incorporating a hypoxia-targeting chemotherapy agent |
| Q35033424 | Value of FDG-PET in the management of non-small cell lung cancer. |
| Q81072386 | [Imaging and PET/CT of lung cancer] |
| Q45950751 | [Proposal for a diagnostic algorithm for the use of (18)F-FDG-PET in lung cancer] |
| Q54102386 | [Role of PET/CT in primitive non-small cell bronchopulmonary cancer]. |
Search more.